Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 27, 2025 03:00 ET | Source: Citryll

Citryll Presents Positive Data from Phase I Study of CIT-013 in Rheumatoid Arthritis at ACR Convergence 2025

CITRYLL PRESENTS POSITIVE DATA FROM PHASE I STUDY OF CIT-013 IN RHEUMATOID ARTHRITIS AT ACR CONVERGENCE 2025 Phase I trial data in rheumatoid arthritis patients demonstrates favorable safety,...
September 02, 2025 02:00 ET | Source: Citryll

FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS

Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis Oss, Netherlands – 2 September 2025 –...
July 24, 2025 02:00 ET | Source: Citryll

Citryll Announces Formation of Scientific Advisory Board

CITRYLL ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD Board comprises world-renowned experts in biology, immunology and pathology Oss, Netherlands – 24 July 2025 – Citryll, a biotech company...
February 20, 2025 02:00 ET | Source: Citryll

Citryll Demonstrates a Broader Therapeutic Potential for CIT-013 in the Treatment of Inflammatory Disorders

CITRYLL DEMONSTRATES A BROADER THERAPEUTIC POTENTIAL FOR CIT-013 IN THE TREATMENT OF INFLAMMATORY DISORDERS Breakthrough study published in Frontiers in Immunology demonstrates CIT-013’s...
December 09, 2024 02:00 ET | Source: Citryll

Citryll Raises EUR 85 Million Series B to Advance Novel NET-Targeting Therapy for Immune-Mediated Inflammatory Disorders

CITRYLL RAISES EUR 85 MILLION SERIES B TO ADVANCE NOVEL NET-TARGETING THERAPY FOR IMMUNE-MEDIATED INFLAMMATORY DISORDERS Financing co-led by Johnson & Johnson Innovation – JJDC, Inc., Forbion and...
October 03, 2024 02:00 ET | Source: Citryll

Citryll and leading rheumatology centres receive Reumanederland grant to collaborate on NET research to advance novel treatments for rheumatoid arthritis.

CITRYLL AND LEADING RHEUMATOLOGY CENTRES RECEIVE REUMANEDERLAND GRANT TO COLLABORATE ON NET RESEARCH TO ADVANCE NOVEL TREATMENTS FOR RHEUMATOID ARTHRITIS Learnings will be used in the clinical...
July 31, 2024 02:00 ET | Source: Citryll

CITRYLL COMPLETES PATIENT DOSING IN THE REPEAT DOSE STAGE OF THE PHASE 1 TRIAL FOR THE NOVEL ANTI-INFLAMMATORY CANDIDATE CIT-013

CITRYLL COMPLETES PATIENT DOSING IN THE REPEAT DOSE STAGE OF THE PHASE 1 TRIAL FOR THE NOVEL ANTI-INFLAMMATORY CANDIDATE CIT-013 Oss, Netherlands – 31 July 2024 – Citryll, a clinical-stage biotech...